Roivant Sciences (NASDAQ:ROIV) Stock Price Down 6.4% - Here's What Happened

Key Points

• Roivant Sciences shares fell 6.4% to $35.17 in mid-day trading, with volume 71% below the stock’s average daily activity.
• The FDA approved and Roivant launched LISRAYA (brepocitinib), described as the first targeted and oral treatment for adult dermatomyositis. The drug carries a U.S. list price of $35,000 per 30-day supply, though commercial success will depend on reimbursement, adoption and launch execution.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating, while Roivant continues to be unprofitable and insiders have sold roughly 2.86 million shares worth $100.1 million over the past 90 days.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) fell 6.4% during mid-day trading on Friday . The company traded as low as $35.17 and last traded at $35.17. 1,707,108 shares were traded during trading, a decline of 71% from the average daily volume of 5,890,813 shares. The stock had previously closed at $37.58.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: The FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis, a rare inflammatory disease affecting the skin and muscles. The once-daily oral treatment is described as the first targeted therapy—and first oral drug—for the condition, giving Roivant and partner Priovant a potentially differentiated product in an underserved market. Reuters FDA approval article
• Positive Sentiment: LISRAYA is now available in the United States, allowing Roivant and Priovant to begin generating commercial revenue rather than relying solely on pipeline milestones. The launch price is $35,000 for a 30-day supply, supporting the possibility of substantial revenue per treated patient, subject to insurance coverage, patient access and adoption. Reuters LISRAYA launch pricing article
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and set a $41 price target, implying roughly 14.7% upside from the cited $35.76 reference price. The endorsement may reinforce investor confidence in LISRAYA’s commercial opportunity. HC Wainwright analyst rating
• Neutral Sentiment: The approval removes a significant regulatory risk, but investors will likely focus next on prescription volume, reimbursement, launch costs and how economics are shared with Priovant and Pfizer. Roivant remains unprofitable, so commercial execution will be important to justify its valuation.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ROIV shares. Citigroup raised their price target on Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Piper Sandler reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, May 21st. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. Guggenheim boosted their target price on Roivant Sciences from $36.00 to $42.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, Sanford C. Bernstein raised Roivant Sciences to a "strong-buy" rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.14.

Roivant Sciences Stock Performance

The company has a market cap of $25.79 billion, a PE ratio of -67.38 and a beta of 1.12. The business's 50-day moving average is $35.09 and its 200 day moving average is $30.88.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Equities research analysts anticipate that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mayukh Sukhatme sold 144,756 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the completion of the sale, the insider directly owned 18,630,739 shares in the company, valued at $679,649,358.72. This represents a 0.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $56,376,551.85. The trade was a 11.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,855,913 shares of company stock worth $100,107,258. Insiders own 8.80% of the company's stock.

Institutional Trading of Roivant Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. SBI Securities Co. Ltd. grew its holdings in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP raised its holdings in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in Roivant Sciences during the 4th quarter valued at $47,000. Parallel Advisors LLC raised its holdings in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock valued at $59,000 after buying an additional 2,665 shares during the period. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source